17,261 trials
Breast Cancer Stage IV · Unresectable Locally Advanced Invasive Breast Cancer · Metastatic Invasive Breast Cancer
Primary: Clinical Benefit Rate — 33 percentage of participants
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
Rotator Cuff Tear
Primary: Change of Pain During Activity From Baseline to 3 Months After Intervention — -1.4; -1.5; -3.0 units on a scale — p=0.35
Systemic Lupus Erythematosus (SLE)
Primary: Percentage of Participants With British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004)-Based Composite Lupus Assessment (BICLA) (mNRI) Response…
Lymphoma
Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants
Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Non-metastatic Renal Cell Carcinoma
Primary: Number of Patients With a Change in Mayo Classification — 6; 15 Participants
Anthrax
Primary: Ratio of Ciprofloxacin Area Under the Curve From 0 to 12 Hours (AUC0-12h) and Maximum Concentration (Cmax) on Days 8 and 35 — 0.9764; 0.9706 Ratio
Lyme Borreliosis
Primary: GMTs (Geometric Mean Titers) for IgG (Immunoglobulin G) Against Each OspA (Outer Surface Protein A) Serotype ST1 to ST6 — 74.3; 101.9; 115.8; 21.7 U/mL
Coronary Artery Disease
Primary: Change From Baseline in Creatinine-normalized u-LTE4 at Week 4 — 0.04; 0.09; 1.09 Ratio — p=<0.001
Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Overall Response Rate (ORR) — 8 percentage of participants
Venous Hypertension Ulcers · Venous Stasis Ulcer · Venous Ulcer
Primary: Number of Participants With Ulcer Recurrence — 6; 3; 11; 5 participants — p=0.091
Chronic Anemia · Transfusional Hemosiderosis
Primary: Absolute Change From Baseline in Liver Iron Concentration (LIC) to Year 1 — -10.9 mg Fe/g dw
Chronic Myelogenous Leukemia · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) · Hypereosinophilic Syndrome
Primary: Number of Participants With Major Cytogenetic Response (MCyR) — 191; 44; 22 Participants
Synovial Sarcoma · Single or Multiple Lung Metastases
Primary: Number of Participants Evaluated for Toxicity — 10 Participants
Carcinoma, Intraductal, Noninfiltrating · DCIS · Ductal Carcinoma In Situ
Primary: Average Change in the Longest Diameter of the Breast MRI Target Lesion — 6; 43 percentage length change